The Tell-Tale Heart: The Pharmacist's Cardiovascular Digest

33: Craig Beavers, PharmD Breaks Down the 2026 CKM Guidelines — And Why They Matter

In this solo episode of the Tell-Tale Heart podcast, host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, delivers an immediate reaction to the newly released 2026 AHA/ACC/ADA/ASN guidelines for cardiovascular kidney metabolic (CKM) syndrome. Beavers calls the document a landmark framework that formally unites obesity, diabetes, chronic kidney disease, heart failure, and atherosclerotic cardiovascular disease into a single disease continuum — a shift he argues changes everything about how clinicians should approach prevention.

32: What's Making Headlines in Cardiovascular Care: A Pharmacist's Breakdown of the Latest Breakthroughs

In this mini news episode of the Tell-Tale Heart podcast, host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, highlights three major developments in cardiovascular and cardiometabolic medicine that pharmacists should have on their radar.

31: From Misdiagnosis to Advocacy: Addressing Bias and Equity in Heart Failure Management

In this episode of The Tell-Tale Heart, host Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, speaks with Rhonda Monroe, MBA, a heart failure survivor and lead advocate at HeartLife, about her lived experience with spontaneous coronary artery dissection (SCAD) and the systemic failures that nearly cost her life. Following the birth of her third child, Monroe experienced classic cardiac symptoms but was repeatedly misdiagnosed as having indigestion or "hysterical motherhood" despite an EKG confirming an acute myocardial infarction.

30: Debriefing ACC 2026: Key Cardiovascular Trials and Their Clinical Implications for Pharmacists

* SPIRIT-HF [https://clinicaltrials.gov/study/NCT04727073]  * CHAMPION-AF [https://clinicaltrials.gov/study/NCT04394546]  * SMART-DECISION [https://clinicaltrials.gov/study/NCT04769362]  * VESALIUS-CV (sub-study) [https://clinicaltrials.gov/study/NCT03872401]  * CORAL REEF [https://clinicaltrials.gov/study/NCT05952869]  * Ez-PAVE [https://clinicaltrials.gov/study/NCT04626973]

29: New Dyslipidemia Guidelines Restore LDL Goals and Expand Pharmacist Opportunities

You can learn more about the 2026 dyslipidemia guidelines here: 2026 Dyslipidemia Guideline Hub | JACC [https://www.jacc.org/guidelines/dyslipidemia]